Association of dyslipidaemia and oral statin use, and dry eye disease symptoms in the Blue Mountains Eye Study

Clin Exp Ophthalmol. 2019 Mar;47(2):187-192. doi: 10.1111/ceo.13388. Epub 2018 Nov 19.

Abstract

Importance: There is limited literature on oral statin use and its association with dry eye.

Background: To analyse the association between dyslipidaemia, use of oral statin drugs, and symptoms of dry eye disease (DED) among older adults.

Design: Population-based study.

Participants: Participants of the Blue Mountains Eye Study III (BMESIII), a large cohort study in suburban Sydney, aged 60 years or older (mean age = 74, range = 60-97, n = 1680) were analysed.

Methods: Information on DED symptoms and statin use were obtained from an interviewer-administered questionnaire. Serum lipid profiles were determined from fasting blood tests.

Main outcome measures: The association of various DED symptoms, as well as their number and their severity, with dyslipidaemia and oral statin intake was evaluated.

Results: At least one DED symptom was reported in 52% (n = 1029) of the population. Patients with hypercholesterolaemia (>5.5 mmol/L) did not report more DED symptoms than those without hypercholesterolaemia. Neither serum high-density lipoprotein nor low-density lipoprotein levels were associated with any DED symptoms. Patients taking oral statins were more likely to report one or more moderate to severe symptoms of DED (odds ratio: 2.054, 95% confidence interval: 1.281-3.295).

Conclusions and relevance: The association between oral statin use and presence of moderate to severe DED symptomatology is a novel finding that deserves further mechanistic and clinical correlation in order to determine its potential, or lack thereof, for the management of dry eye.

Keywords: Meibomian gland dysfunction; dyslipidaemia; hypercholesterolaemia; lipid; statin.

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Cross-Sectional Studies
  • Dry Eye Syndromes / chemically induced*
  • Dry Eye Syndromes / diagnosis
  • Dyslipidemias / chemically induced*
  • Dyslipidemias / diagnosis
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hypercholesterolemia / drug therapy
  • Lipids / blood
  • Male
  • Middle Aged
  • New South Wales / epidemiology
  • Odds Ratio
  • Retrospective Studies
  • Surveys and Questionnaires

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids